BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 24151143)

  • 1. The use and acceptance of Other Scientifically Relevant Information (OSRI) in the U.S. Environmental Protection Agency (EPA) Endocrine Disruptor Screening Program.
    Bishop PL; Willett CE
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):3-22. PubMed ID: 24151143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of EPA's Tier 1 Endocrine Screening Battery and recommendations for improving the interpretation of screening results.
    Borgert CJ; Mihaich EM; Quill TF; Marty MS; Levine SL; Becker RA
    Regul Toxicol Pharmacol; 2011 Apr; 59(3):397-411. PubMed ID: 21251942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Key learnings from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 in vitro assays.
    LeBaron MJ; Coady KK; O'Connor JC; Nabb DL; Markell LK; Snajdr S; Sue Marty M
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):23-42. PubMed ID: 24515815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of an integrated testing strategy to the U.S. EPA endocrine disruptor screening program.
    Willett CE; Bishop PL; Sullivan KM
    Toxicol Sci; 2011 Sep; 123(1):15-25. PubMed ID: 21642633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introduction to "screening for endocrine activity-experiences with the US EPA's endocrine disruptor screening program and future considerations".
    Marty S
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):1-2. PubMed ID: 24510782
    [No Abstract]   [Full Text] [Related]  

  • 6. Key lessons from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 male and female pubertal assays.
    Stump DG; O'Connor JC; Lewis JM; Marty MS
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):43-62. PubMed ID: 24510766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons learned, challenges, and opportunities: the U.S. Endocrine Disruptor Screening Program.
    Juberg DR; Borghoff SJ; Becker RA; Casey W; Hartung T; Holsapple MP; Marty MS; Mihaich EM; Van Der Kraak G; Wade MG; Willett CE; Andersen ME; Borgert CJ; Coady KK; Dourson ML; Fowle JR; Gray LE; Lamb JC; Ortego LS; Schug TT; Toole CM; Zorrilla LM; Kroner OL; Patterson J; Rinckel LA; Jones BR
    ALTEX; 2014; 31(1):63-78. PubMed ID: 24114257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypothesis-driven weight of evidence evaluation indicates styrene lacks endocrine disruption potential.
    Borgert CJ
    Crit Rev Toxicol; 2023 Feb; 53(2):53-68. PubMed ID: 37216681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A predictive data-driven framework for endocrine prioritization: a triazole fungicide case study.
    Paul Friedman K; Papineni S; Marty MS; Yi KD; Goetz AK; Rasoulpour RJ; Kwiatkowski P; Wolf DC; Blacker AM; Peffer RC
    Crit Rev Toxicol; 2016 Oct; 46(9):785-833. PubMed ID: 27347635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of EPA's endocrine screening battery and recommendations for further review.
    Schapaugh AW; McFadden LG; Zorrilla LM; Geter DR; Stuchal LD; Sunger N; Borgert CJ
    Regul Toxicol Pharmacol; 2015 Aug; 72(3):552-61. PubMed ID: 26044367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of Adverse Outcome Pathways to U.S. EPA's Endocrine Disruptor Screening Program.
    Browne P; Noyes PD; Casey WM; Dix DJ
    Environ Health Perspect; 2017 Sep; 125(9):096001. PubMed ID: 28934726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chlorpyrifos: weight of evidence evaluation of potential interaction with the estrogen, androgen, or thyroid pathways.
    Juberg DR; Gehen SC; Coady KK; LeBaron MJ; Kramer VJ; Lu H; Marty MS
    Regul Toxicol Pharmacol; 2013 Aug; 66(3):249-63. PubMed ID: 23524272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uncertainties for endocrine disrupters: our view on progress.
    Daston GP; Cook JC; Kavlock RJ
    Toxicol Sci; 2003 Aug; 74(2):245-52. PubMed ID: 12730617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FIFRA Subdivision F testing Guidelines: are these tests adequate to detect potential hormonal activity for crop protection chemicals? Federal Insecticide, Fungicide, and Rodenticide Act.
    Stevens JT; Tobia A; Lamb JC; Tellone C; O'Neal F
    J Toxicol Environ Health; 1997 Apr; 50(5):415-31. PubMed ID: 9140462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine profiling and prioritization of environmental chemicals using ToxCast data.
    Reif DM; Martin MT; Tan SW; Houck KA; Judson RS; Richard AM; Knudsen TB; Dix DJ; Kavlock RJ
    Environ Health Perspect; 2010 Dec; 118(12):1714-20. PubMed ID: 20826373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening Chemicals for Estrogen Receptor Bioactivity Using a Computational Model.
    Browne P; Judson RS; Casey WM; Kleinstreuer NC; Thomas RS
    Environ Sci Technol; 2015 Jul; 49(14):8804-14. PubMed ID: 26066997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance weighting of tier 1 endocrine screening endpoints by rank order.
    Borgert CJ; Stuchal LD; Mihaich EM; Becker RA; Bentley KS; Brausch JM; Coady K; Geter DR; Gordon E; Guiney PD; Hess F; Holmes CM; LeBaron MJ; Levine S; Marty S; Mukhi S; Neal BH; Ortego LS; Saltmiras DA; Snajdr S; Staveley J; Tobia A
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):90-113. PubMed ID: 24510745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scientific and Regulatory Policy Committee (SRPC) Points to Consider: Histopathology Evaluation of the Pubertal Development and Thyroid Function Assay (OPPTS 890.1450, OPPTS 890.1500) in Rats to Screen for Endocrine Disruptors.
    Keane KA; Parker GA; Regan KS; Picut C; Dixon D; Creasy D; Giri D; Hukkanen RR
    Toxicol Pathol; 2015 Dec; 43(8):1047-63. PubMed ID: 25948506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using in vitro high throughput screening assays to identify potential endocrine-disrupting chemicals.
    Rotroff DM; Dix DJ; Houck KA; Knudsen TB; Martin MT; McLaurin KW; Reif DM; Crofton KM; Singh AV; Xia M; Huang R; Judson RS
    Environ Health Perspect; 2013 Jan; 121(1):7-14. PubMed ID: 23052129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key learnings from the Endocrine Disruptor Screening Program (EDSP) Tier 1 rodent uterotrophic and Hershberger assays.
    Marty MS; O'Connor JC
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):63-79. PubMed ID: 24515841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.